secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2025-09-29T23:59:59+00:00
Accession:  0001104659-25-094109
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 5.03, 3.02, 3.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dogwood Therapeutics licenses SP16 for CIPN in all-stock deal; NCI funds Phase 1b
--------------------------------------------------------------------------------

- Royalty-free global license from Serpin Pharma for SP16, a first-in-class LRP1 agonist targeting chemotherapy-induced peripheral neuropathy (CIPN).
- Consideration: 382,034 common shares + 179.1878 Series A-2 Preferred shares (convert 1:10,000), representing 7.31% fully diluted.
- Phase 1b CIPN study fully funded by NCI; patient enrollment projected first half 2026.
- Halneuron Phase 2b ongoing (80 patients randomized); interim data from 90-100 patients expected December 2025.
- Support agreements with Serpin, Tungsten, and Sealbond to vote for stockholder approval of preferred stock conversions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000110465925094109/0001104659-25-094109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000110465925094109/dwtx-20250929x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-094109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer